In addition, compared with NSCLC, the utilization rates within 3 months before first discharge with diagnosed SCLC were relatively high with around 75% for CEA, Cyfra21‐1, and NSE, 64.6% for SCC, and 30.7% for ProGRP (Figure 3). This evidence concerns the gene ENO2 and non-small cell lung carcinoma.